Medicyte, Reinnervate Partner on Cell-based Assay Technologies | GenomeWeb

NEW YORK (GenomeWeb News) – Medicyte and Reinnervate today announced a collaboration to combine their technologies, bringing a next generation of cell-based assays to the biopharma and academic research markets.

The partnership brings together Medicyte's upcyte technology and Reinnervate's Alvetex Scaffold technologies. Upcyte are genetically engineered "upregulated" primary cells, and according to Medicyte, data suggests that upcyte hepatocytes combine the benefits of quantity — up to 2,000 vials per donor can be generated — and the quality of primary hepatocytes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.